149 related articles for article (PubMed ID: 2937009)
1. [Haloperidol. Plasma monitoring and hormonal effects of treatment].
Goyot C; Debray Q; Dugas M; Guay C; Giraud J; Grenier J
Pathol Biol (Paris); 1985 Dec; 33(10):999-1004. PubMed ID: 2937009
[TBL] [Abstract][Full Text] [Related]
2. Influence of route of administration on haloperidol plasma levels in psychotic patients.
Bianchetti G; Zarifian E; Poirier-Littre MF; Morselli PL; Deniker P
Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):324-7. PubMed ID: 7429678
[TBL] [Abstract][Full Text] [Related]
3. [Effects of intrathecal injection of beta-endorphin on endocrine function in man (author's transl)].
Yamaya R
Masui; 1981 May; 30(5):445-52. PubMed ID: 6268860
[No Abstract] [Full Text] [Related]
4. [Use of very high doses of haloperidol in the treatment of acute psychotic episodes. Clinical and pharmacokinetic analysis apropos of 15 cases].
Petit P; Blayac JP; Castelnau D; Billet J; Puech R; Pouget R
Encephale; 1987; 13(3):127-30. PubMed ID: 3595515
[TBL] [Abstract][Full Text] [Related]
5. [Plasma monitoring of haloperidol. Correlation with clinical efficacy and plasma prolactin levels].
Giraud-Serio J; Goyot C; Debray Q; Plaisant O; Grenier J; Pélicier Y
Ann Med Psychol (Paris); 1985 Nov; 143(9):900-11. PubMed ID: 3834819
[No Abstract] [Full Text] [Related]
6. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
7. [Standard and high doses of haloperidol. Clinical, pharmacokinetic and pharmacodynamic aspects].
Schilkrut R; Haverbeck C; Duran E; Delgado S; Kohen P; Birkner R; Katz I
Acta Psiquiatr Psicol Am Lat; 1981; 27(4-5):315-24. PubMed ID: 7348089
[TBL] [Abstract][Full Text] [Related]
8. [Plasma level monitoring of psychotropic drugs in children. I-Haloperidol (author's transl)].
Dugas M; Zarifian E; Le Heuzey MF; Regnier N; Durand G; Bianchetti G; Morselli PL
Nouv Presse Med; 1982 Jun; 11(29):2201-4. PubMed ID: 7110982
[TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of haloperidol and prolactin and clinical outcome in acutely psychotic patients.
Aschauer HN; Schönbeck G; Langer G; Koinig G; Resch F; Hatzinger R; Chaudry HR; Sieghart W
Pharmacopsychiatry; 1988 Sep; 21(5):246-51. PubMed ID: 3227055
[TBL] [Abstract][Full Text] [Related]
10. Correlates of early neuroleptic response using a uniform haloperidol dose.
Bowers MB; Swigar ME; Jatlow PI; Hoffman FJ; Goicoechea N
Int Clin Psychopharmacol; 1987 Jul; 2(3):255-60. PubMed ID: 3693868
[TBL] [Abstract][Full Text] [Related]
11. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
McEvoy JP; Stiller RL; Farr R
J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
[TBL] [Abstract][Full Text] [Related]
12. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
13. Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms.
Neborsky RJ; Janowsky DS; Perel JM; Munson E; Depry D
J Clin Psychiatry; 1984 Jan; 45(1):10-3. PubMed ID: 6363395
[TBL] [Abstract][Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
15. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children.
Ernst M; Devi L; Silva RR; Gonzalez NM; Small AM; Malone RP; Campbell M
Psychopharmacol Bull; 1993; 29(2):221-7. PubMed ID: 8290669
[TBL] [Abstract][Full Text] [Related]
16. [Measurement of basal plasma levels of 3 anterior pituitary hormones during acute or chronic treatment with tricyclic antidepressants].
Goyot C; Debray Q; Hug R; Grenier J
Encephale; 1985; 11(2):45-51. PubMed ID: 4017937
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic of haloperidol decanoate in psychotic patients (author's transl)].
Parent M; Toussaint C; Driesens F; Gelders Y
Acta Psychiatr Belg; 1981; 81(4):399-406. PubMed ID: 7331843
[No Abstract] [Full Text] [Related]
18. [Towards an attempt at biological differentiation of endogenous and exogenous depression: a study of beta-endorphins and other parameters (prolactin, growth hormone and dexamethasone repression test) in a cohort of ambulatory depressed patients].
Gallart JM; Galard R; Catalan R; Arguello JM; Castellanos JM; Schwartz S
Ann Med Psychol (Paris); 1988; 146(8):758-63. PubMed ID: 2977276
[No Abstract] [Full Text] [Related]
19. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
Meco G; Casacchia M; Attenni M; Iafrate A; Castellana F; Ecari U
Acta Psychiatr Belg; 1983; 83(1):57-68. PubMed ID: 6613612
[TBL] [Abstract][Full Text] [Related]
20. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
